Tomas Fait

Dr. Tomas Fait

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2019 in Drugs in Context
Verified
Journal Article
Open access
TFTomas Fait
Tomas Fait
Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors.

22 November 2013 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
JBJana Bartáková
Jana Bartáková
EPEliska Potlukova
Eliska Potlukova
VRVladimir Rogalewicz
Vladimir Rogalewicz
TFTomas Fait
Tomas Fait
DSDita Schöndorfová
Dita Schöndorfová
JJJan Jiskra
Jan Jiskra
Hypothyroidism and/or autoimmune thyroid disorders (AITD) may contribute to spontaneous abortions (SpA). Cost-effectiveness analyses of thyroid screening in women after SpA are lacking. Our aim was to evaluate the cost-effectiveness of screening for AITD and/or hypothyroidism and their treatment in women after SpA with regard to their reproductive health.

AŠAnna Šťastná
Anna Šťastná
TFTomas Fait
Tomas Fait
JKJiřina Kocourková
Jiřina Kocourková
EWEva Waldaufová
Eva Waldaufová
Objective: To investigate the association between a mother’s age and the risk of caesarean section (CS) when controlling for health factors and selected sociodemographic characteristics. Methods: Binary logistic regression models for all women who gave birth in Czechia in 2018 (N = 111,749 mothers who gave birth to 113,234 children). Results: An increase in the age of a mother significantly increases the odds of a CS birth according to all of the models; depending on the model, OR: 1.62 (95% CI 1.54–1.71) to 1.84 (95% CI 1.70–1.99) for age group 35–39 and OR: 2.83 (95% CI 2.60–3.08) to 3.71 (95% CI 3.23–4.27) for age group 40+ compared to age group 25–29. This strong association between the age of a mother and the risk of CS is further reinforced for primiparas (probability of a CS: 11% for age category ≤ 19, 23% for age category 35–39, and 38% for age category 40+). However, the increasing educational attainment of young women appears to have weakened the influence of increasing maternal age on the overall share of CS births; depending on the model, OR: 0.86 (95% CI 0.80–0.91) to 0.87 (95% CI 0.83–0.91) for tertiary-educated compared to secondary-educated women. Conclusions: The age of a mother comprises an independent risk factor for a CS birth when the influence of health, socioeconomic, and demographic characteristics is considered.

1 November 2006 in Fetal Diagnosis and Therapy
Verified
Journal Article
Closed access
ZZZdenek Zizka
Zdenek Zizka
PCPavel Calda
Pavel Calda
TFTomas Fait
Tomas Fait
LHLucia Haakova
Lucia Haakova
JKJan Kvasnicka
Jan Kvasnicka
HVHana Viskova
Hana Viskova
Introduction: Lymphocyte subpopulations are identified by the uniform CD classification (Cluster of Differentiation) and can be accurately differentiated with monoclonal antibodies using the method of flow cytometry. With the aid of cordocentesis it is possible to perform studies on the status and development of cellular immunity as early as in the second trimester of pregnancy. Objective: To compare lymphocyte subpopulations present in fetuses with chromosomal abnormalities (Down’s syndrome (DS), Edwards’ syndrome (ES)) and fetuses with normal karyotype. Study Design: Prospective observational study. Methods: We examined a total of 61 pregnant women with an average age of 31.5 years (20– 46 years). Results: In fetuses with DS we found a significant decrease in B lymphocytes (CD19),a decrease in the subpopulations of multi-reactive B-cells (CD5+CD19+, B-CLL),and a decrease in the index of CD4/CD8 and class II HLA-DR. In contrast, the representation of NK cells expressing /CD3-CD (16 + 56)+/ was greatly increased. In ES we found a decrease in T lymphocytes (CD3), a decrease in T-helper lymphocytes (monocytes CD4), a decreased index of CD4/CD8 and a greater representation of NK cells /CD3-CD (16 + 56)+/. Conclusion: We determined the normal values of lymphocyte subpopulations in physiological fetuses. We demonstrated that the immunological defect of the affected fetuses is already present antenatally, and can be reliably diagnosed in the second trimester of pregnancy.

1 February 2015 in Clinica Chimica Acta
Verified
Journal Article
Closed access
JHJaroslav A Hubacek
Jaroslav A Hubacek
JRJitka Rynekrova
Jitka Rynekrova
DKDita Kasparova
Dita Kasparova
VAVera Adamkova
Vera Adamkova
MHMichael V. Holmes
Michael V. Holmes
TFTomas Fait
Tomas Fait

28 September 2021 in Phytotherapy Research
Verified
Journal Article
Open access
PDF file
IMIngrid Melnikovova
Ingrid Melnikovova
DRDaniela Russo
Daniela Russo
TFTomas Fait
Tomas Fait
MKMichaela Kolarova
Michaela Kolarova
JTJan Tauchen
Jan Tauchen
ECEloy Fernández Cusimamani
Eloy Fernández Cusimamani
Male infertility refers to the inability to conceive a natural pregnancy in a fertile female, and approximately 15% of reproductive‐aged couples worldwide face this problem. Several plants were used to treat fertility disorders and, among them, Lepidium meyenii, a folk medicament of Andean regions, is still used to enhance vitality and treat sterility in humans and domestic animals. The aim of the study was to evaluate the effects of L. meyenii Walpers on infertile patients by a randomized, double‐blind, placebo‐controlled trial. Fifty patients suffering from various reproductive‐related problems were enrolled for 16 weeks to evaluate the effect of yellow maca on semen quality and serum hormone levels. Treatment with maca improved the percentage of sperm concentration by 40%, whereas the placebo improved by 76% after 8 and 16 weeks of treatment, but the results were statistically non‐significant. No statistically significant change in hormone levels was reported by using maca, except a decrease in the level of free testosterone. Results are not sufficient to assess the efficacy of maca on male fertility. Further investigation and trials are required to obtain conclusive results.